Joe Durak

$MEM just quietly delivered another knockout milestone today ...and this one matters more than most people realise. TGA APPROVAL ACHIEVED. Felix™ is now officially approved and listed on the ARTG, enabling immediate commercial sales and clinical deployment across Australia.... and it landed 2 months ahead of guidance. Why this is such a big deal: • Australia is a high-regulatory, high-credibility IVF market • Approval came early, compressing time to revenue • Clinics can now be onboarded, consoles deployed, cartridges sold right now Zoom out for a second and look at the sequence: 1️⃣ CE Mark approved → Europe + CE-recognised markets unlocked 2️⃣ Binding multi-year contracts activated (Europe + MENA) 3️⃣ Early cartridge orders placed ahead of triggers 4️⃣ Clinics trained and “switch-ready” 5️⃣ Australia approved earlier than expected This is exactly how serious medtechs scale ....regulatory, commercial and operational alignment, all landing together. Felix™ isn’t waiting on “next steps” anymore. It’s approved, deployable, contracted, and already being pulled by clinics. Australia now becomes: • A live reference market • A revenue-generating region • A credibility amplifier for global rollout And with Europe + MENA already activated, and India following under CE mutual recognition, this story is now about rollout and repeat usage... $MEM still feels very cheap relative to where it is in its lifecycle ... but more importantly, it’s now fully derisked operationally. This is what a transition from development → execution actually looks like. DYOR.

$MEM is getting very real now — execution mode ON. New contracts and expansion updates dropping almost every week. 🚨 Today’s India update confirms it again $MEM has just secured a commercial supply agreement with Andrology Center Coimbatore, one of India’s most respected IVF networks with 200+ partner clinics across 57 locations. Key details: ✅ Year 1 minimum commitment — 1,800 Felix™ cartridges (A$98,820) ✅ Year 2 locked at ≥ 50% growth — 2,700+ cartridges ✅ Dedicated India-based Felix™ commercial team being set up to aggressively drive adoption ✅ Builds on proven live births already delivered using Felix™ (first in 2023) ✅ Agreement activates on CE Mark + CDSCO approvals (expected early 2026) This follows the recent multi-year MENA partnership covering 353 IVF clinics / 140,000 annual cycles, with a binding A$325k order already secured on CE approval. $MEM is now rolling out a global Go-Direct commercial strategy across Middle East + India + Japan + NZ — locking in contracted, recurring cartridge revenue across multiple major fertility markets. This is, without question, one of the most undervalued commercial-stage medtech / biotech plays on the entire ASX right now. Execution is accelerating, not theorising — Felix™ is now moving into revenue mode. And yes — $MEM is firmly in my next-wave biotech focus alongside $IBX, $ADR, $IVX. My $4DX (6 bags heads / 50 bags options) & $ATX success is EXACTLY why I’m positioned here early. This story is just getting started. DYOR